New York State Teachers Retirement System Has $95.42 Million Position in Bristol Myers Squibb Company $BMY

New York State Teachers Retirement System cut its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,768,989 shares of the biopharmaceutical company’s stock after selling 69,608 shares during the quarter. New York State Teachers Retirement System’s holdings in Bristol Myers Squibb were worth $95,419,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Man Group plc raised its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Two Sigma Investments LP boosted its position in Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after buying an additional 4,588,601 shares during the last quarter. Van ECK Associates Corp boosted its position in Bristol Myers Squibb by 67.8% in the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock valued at $444,682,000 after buying an additional 3,982,439 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Bristol Myers Squibb by 31.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock valued at $669,012,000 after buying an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 56.0% during the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after acquiring an additional 3,396,041 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 5.5%

NYSE:BMY opened at $60.75 on Friday. The company has a market cap of $124.04 billion, a PE ratio of 17.61, a PEG ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock has a 50-day simple moving average of $59.56 and a 200 day simple moving average of $54.48. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the company earned $1.80 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.27 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BMY. Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target on the stock. Leerink Partners upped their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. HSBC boosted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $61.31.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY beat Q1 profit and revenue estimates, driven by growth‑portfolio drugs and Eliquis strength — a primary catalyst for the stock lift. Bristol Myers posts higher-than-expected quarterly profit
• Positive Sentiment: Company released Q1 results and slide deck, showing revenue of $11.49B and non‑GAAP EPS $1.58 — both above estimates — and reiterated FY2026 EPS guidance (6.05–6.35). Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Positive Sentiment: Management sounded confident on the Q1 call, highlighting cost‑cutting progress and growth‑portfolio commercialization that support near‑term outlook. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Partnership expansion with Foundation Medicine on MTAP CDx strengthens BMY’s precision‑oncology positioning and could aid targeted pipeline development. Does BMS–Foundation Medicine’s MTAP CDx Partnership Expansion Change The Bull Case For Bristol-Myers Squibb (BMY)?
• Neutral Sentiment: Street consensus price target around $61.31 — roughly in line with the stock’s current level, implying limited near‑term upside from analyst targets alone. Bristol Myers Squibb Receives $61.31 Consensus PT from Analysts
• Neutral Sentiment: Bernstein maintains a Hold rating, reflecting a cautious view despite recent operational beats. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Detailed Q1 slides and earnings transcript are available for investors wanting line‑item visibility into product performance and margin trends. Bristol-Myers Squibb Company 2026 Q1 – Results – Earnings Call Presentation
• Negative Sentiment: Analysts and industry commentary flag a major Eliquis patent cliff ahead — a material long‑term revenue risk that could pressure future sales as generics enter. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: While EPS guidance was reaffirmed, the midpoint of full‑year revenue guidance came in slightly below analysts’ expectations — a nuance that could limit upside if growth disappoints. Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.